Multiple sclerosis: Care needs for 2000 and beyond

Journal of the Royal Society of Medicine

Volumn 93, Issue 5, 2000, Pages 219-224

  Nodder, David G ^a,b,j   Chappell, Brian ^a,c   Bates, David ^d   Freeman, Jenny ^e   Hatch, Jan ^f   Keen, John ^g   Thomas, Sue ^h   Young, Carolyn ⁱ  

^a LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^b NEUROEDUCATON   (United Kingdom)

^c NEUROEDUCATION   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e UNIVERSITY OF PLYMOUTH   (United Kingdom)

^f Great Britain and Northern Ireland   (United Kingdom)

^g Bedford Park Surgery   (United Kingdom)

^h ROYAL COLLEGE OF NURSING   (United Kingdom)

ⁱ WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^j NEUROEDUCATION   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; AZATHIOPRINE; BACLOFEN; CAPSAICIN; CARBAMAZEPINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANTROLENE; DESMOPRESSIN; DIAZEPAM; GABAPENTIN; GLATIRAMER; INTERFERON; OXYBUTYNIN; PAPAVERINE; PEMOLINE; PHENTOLAMINE; PHENYTOIN; PROSTAGLANDIN E1; SILDENAFIL; TIZANIDINE; VALPROIC ACID; VIGABATRIN;

BLADDER DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTRACTURE; DECUBITUS; DEPRESSION; DISEASE COURSE; FATIGUE; HUMAN; IMPOTENCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHYSICAL DISABILITY; PHYSIOTHERAPY; RELAPSE; REVIEW; SPASTICITY; TEMPERATURE SENSITIVITY; TREMOR; VISUAL DISORDER;

EID: 0034025239     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680009300502     Document Type: Review

References (28)

1. 1 Lublin FD, Reingold SC. Defining the clinical course of MS: results of an international study. Neurology 1996;46:907-11
2. 2 Poser CM. New diagnostic criteria for MS - guidelines for research protocols. Ann Neurol 1983;13:227-31
3. 3 Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing MS. Brain 1998;121:3-24
4. 4 Johnson J. What can specialist nurses offer in caring for people with MS? In: Thompson AJ, Polman C, Hohfield R, eds. MS - Clinical Challenges and Controversies. London: Dunitz, 1997:335-43
5. 5 Thomas S. The role of the specialist nurse in the management of MS. Everyday Neurol 1997;(suppl. 2D)
6. 6 Robinson T, Hunter M, Neilson S. A Dispatch from the Front Line - the Views of People with MS about their Needs. A Qualitative Approach. A Report for The MS Society. Brunel: MS Research Unit, 1996
7. 7 Audit Commission. Briefing - A Review of District Nursing Services in England & Wales. London: AC, 1999
8. 8 Barnes MP. Standards in neurological rehabilitation. Europ J Neurol 1997;4:325-31
9. 9 Nolan M, Nolan J. Rehabilitation in MS: the potential nursing contribution. Br J Nursing 1997;6:1292-5
10. 10 Freeman JA, Langdon DW, Hobart JC, Thompson AJ. The impact of inpatient rehabilitation on progressive MS. Ann Neurol 1997;42:236-44
11. 11 Rossiter DA, Edmondson A, al-Shahi R, Thompson AJ. Integrated care pathways in MS rehabilitation: completing the audit cycle. Multiple Sclerosis 1998;4:85-9
12. 12 Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue and functional status for persons with progressive MS. Arch Phys Med Rehab 1998;79:141-6
13. 13 Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive MS. BMJ 1999;319:1529-33
14. 14 Schwartz CE, Coutard-Morris L, Zeng Q. Psychosocial correlates of fatigue in MS. Arch Phys Med Rehab 1996;77:165-70
15. 15 Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in MS. J Neurol Neurosurg Psych 1993;56:245-50
16. 16 Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994;57:773-7
17. 17 Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989;320:1517-21
18. 18 Vermote R, Ketelaer P, Carlton H. Pain in MS patients. Clin Neurol Neurosurg 1986;88:87-93
19. 19 Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive function in MS - frequency patterns and prediction. Neurology 1991;41:685-91
20. 20 Schiffer RB, Babigian HM. Behavioral disorders in MS, temporal lobe epilepsy and amyotrophic lateral sclerosis. Arch Neurol 1984;41:1067-9
21. 21 Compston DAS. MS: Working party report of the British Society of Rehabilitation Medicine. London: BJRM, 1993
22. 22 Polman CH, Bertelsmann FW, Locnen AC, Koetsier JC. 4-aminopyridine in treatment of MS patients - long term efficacy and safety. Arch Neurol 1994;S1:292-6
23. 23 Rice GPA, Lesaux J, Vandervoort P, Macewan L, Ebers GC. Ondansetron, a 5-HT3 antagonist improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997;62:282-4
24. 24 Freeman J, Johnson J, Rollinson S, Thompson AJ. Standards of Healthcare for People with MS. London: MS Society and Neurorehabilitation and Therapy Services Directorate of the National Hospital for Neurology and Neurosurgery, 1997
25. 25 Swain SE. MS: Primary health care implications. Nurse Practitioner 1996;21:40-50
26. 26 Holmes J, Madgewick T, Bates D. The cost of MS. Br J Med Econ 1995;8:181-93
27. 27 Walley T, Barton S. A purchaser perspective of managing new drugs; interferon beta as a case study. BMJ 1995;311:796-9
28. 28 Rous E, Coppel A, Hawarth J, Noyce S. A purchaser experience of managing new, expensive drugs; interferon beta. BMJ 1996;313:1195-6